Juno Therapeutics, Inc. (NASDAQ:JUNO) has earned a consensus recommendation of “Hold” from the nineteen brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $49.86.

JUNO has been the subject of several recent analyst reports. BTIG Research upgraded shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a research note on Monday, August 28th. Zacks Investment Research cut shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 28th. Wells Fargo & Company reiterated an “outperform” rating and issued a $54.00 price objective (up previously from $35.00) on shares of Juno Therapeutics in a research note on Tuesday, September 5th. Barclays PLC initiated coverage on shares of Juno Therapeutics in a research note on Wednesday, September 6th. They issued an “overweight” rating and a $55.00 price objective for the company. Finally, Raymond James Financial, Inc. raised their price objective on shares of Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/22/juno-therapeutics-inc-juno-receives-49-86-consensus-price-target-from-analysts.html.

Shares of Juno Therapeutics (JUNO) traded up $1.56 during midday trading on Friday, hitting $60.33. 749,177 shares of the company traded hands, compared to its average volume of 2,048,147. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $61.59.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter last year, the business earned ($0.57) earnings per share. The business’s revenue for the quarter was up 115.4% compared to the same quarter last year. research analysts anticipate that Juno Therapeutics will post -4.02 EPS for the current fiscal year.

In other news, EVP Robert Azelby sold 6,666 shares of Juno Therapeutics stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total transaction of $366,296.70. Following the completion of the sale, the executive vice president now directly owns 79,998 shares in the company, valued at $4,395,890.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Bernard J. Cassidy sold 28,000 shares of Juno Therapeutics stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the sale, the general counsel now owns 55,970 shares of the company’s stock, valued at $2,514,172.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 79,670 shares of company stock valued at $3,553,777. Insiders own 15.26% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Utah Retirement Systems grew its holdings in shares of Juno Therapeutics by 1.8% during the second quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 200 shares in the last quarter. State of Wisconsin Investment Board grew its holdings in shares of Juno Therapeutics by 1.7% during the second quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 210 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares in the last quarter. Aperio Group LLC grew its holdings in shares of Juno Therapeutics by 4.2% during the third quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 1,194 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Juno Therapeutics by 9.5% during the third quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 1,328 shares in the last quarter. Institutional investors and hedge funds own 66.96% of the company’s stock.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.